NewsRx

Search our medical news database

Colon Cancer

Fecal occult blood test for colon cancer acquired from Alfa Scientific Designs

Published in Cancer Weekly, November 1st, 2005

Quidel Corporation (QDEL) announced its entrance into the rapid test market for determining the presence of blood in stool specimens as an aid in colorectal cancer screening.

Quidel has acquired the immunochemical fecal occult blood test (iFOBT) from Alfa Scientific Designs, Inc. of Poway, California. This U.S. Food and Drug Administration (FDA) cleared and CLIA-waived test (which validates clinical efficacy and ease of use) will be marketed to healthcare professionals as the QuickVue iFOB test.

The immunochemical fecal occult blood test category represents a large market opportunity for Quidel as over 50 million fecal occult blood tests are sold...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook